evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

74 questions · 77 findings · 5 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 32 · 41.6%GRADE not reported 1 · 1.3%Very low 20 · 26%Low 17 · 22.1%Moderate 7 · 9.1%High 0 · 0%

Summary of findings: pioglitazone monotherapy vs placebo

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy may leads to lower incidence of T2DM (N) Diagnostic criteria: 3 studies applied the WHO… compared with placebo (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs placebo

Cardiovascular mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes cardiovascular mortality (N) compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs placebo

Non‐fatal myocardial infarction/stroke · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes non‐fatal myocardial infarction/stroke (N) compared with placebo (very low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs no intervention

All‐cause mortality · people at increased risk for developing type 2 diabetes

It is very uncertain whether summary of findings: pioglitazone monotherapy changes all‐cause mortality (N) compared with no intervention (very low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs no intervention

Incidence of T2DM (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy probably leads to lower incidence of T2DM (N) Diagnostic criteria: 9 studies applied the WHO… compared with no intervention (moderate certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs no intervention

Serious adverse events (N) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in serious adverse events (N) compared with no intervention (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Metformin Diagnostic criteria: 2 studies applied the WHO 1999 criteria for 'prediabetes' (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a; Zeng 2013) · people at increased risk for developing type 2 diabetes

Summary of findings: pioglitazone monotherapy showed no clear difference in metformin Diagnostic criteria: 2 studies applied the WHO 1999… compared with another pharmacological glucose‐lowering monotherapy (low certainty).

1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Acarbose Diagnostic criteria: 1 study applied the WHO 1999 criteria for prediabetes (FPG > 6.1 mmol/L and < 7.0 mmol/L and/or a 2‐h glucose < 11.1 mmol/L after a 75 g OGTT; Chen 2007a) · people at increased risk for developing type 2 diabetes
1 finding from 1 review

Summary of findings: pioglitazone monotherapy vs another pharmacological glucose‐lowering monotherapy

Repaglinide Diagnostic criteria: 1 study applied the ADA 2010 criteria (FPG ≥ 5.6 mmol/L and < 6.9 mmol/L and 2‐h glucose ≥ 7.8 mmol/L or < 11.0 mmol/L after a 75 g OGTT; Zhang 2007) · people at increased risk for developing type 2 diabetes
1 finding from 1 review